While the majority of children and adolescents with newly diagnosed childhood acute
lymphoblastic leukemia (ALL) will be cured, as many as 20% of patients will experience …

The development of effective therapy for children with acute lymphoblastic leukemia is one
of the great successes of clinical hematology andoncology. Fifty years ago, childhood acute …

Childhood acute lymphoblastic leukemia (ALL) is the most common malignancy of
childhood. Studies in ALL have been a model for clinical and basic research beyond …

Introduction: During recent decades, the prognosis of childhood acute lymphoblastic
leukemia (ALL) has improved dramatically, nowadays, reaching a cure rate of almost 90 …

Acute lymphoblastic leukemia (ALL) is the most common malignancy of childhood with a
peak incidence between 2 and 6 years of age. Recent advances in understanding the …

During the past decade, advances in the treatment of childhood acute lymphoblastic
leukemia (ALL) have continued, largely due to improved disease‐free survival of poor …

Improved supportive care, more precise risk stratification, and personalized chemotherapy
based on the characteristics of leukemic cells and hosts (eg, pharmacokinetics and …

With improved contemporary therapy, we reassess long-term outcome in patients
completing treatment for childhood acute lymphoblastic leukemia (ALL) to determine when …

Intensive chemotherapy regimens for children with acute lymphoblastic leukemia (ALL) have
greatly improved, and the majority of children with precursor B-cell ALL are able to achieve a …

This article discusses ways in which pediatric patients with acute lymphoblastic leukemia
(ALL) can be stratified to receive intensive and less intensive therapies in order to decrease …